Alya Nafis, Bismar Al Bara, Deviana Farhani, Dhavina Maharani, Fajar Prasetyo, Galih
Ibnu Mukti, Nur Sa’diyyah
830 Syntax Idea, Vol.4, No. 4, April 2022
Castellino, S., Moss, L., Wagner, D., Borland, J., Song, I., Chen, S., ... & Savina, P. M.
(2013). Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor
dolutegravir in humans. Antimicrobial agents and chemotherapy, 57(8), 3536-
3546. Google Scholar
Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, PoizotMartin I,
Richmond G, Soriano V, Ait-Khaled M, Fugiwara T, Huang J, Min S, Vavro C,
Yeo J. 2013. Safety and efficacy of dolutegravir in treatment-experienced subjects
with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING
study. J. Infect. Dis. Google Scholar
Grégoire, M., Deslandes, G., Renaud, C., Bouquié, R., Allavena, C., Raffi, F., Jolliet,
P., & Dailly, E. (2014). A liquid chromatography–tandem mass spectrometry assay
for quantification of rilpivirine and dolutegravir in human plasma. Journal of
Chromatography B, 971, 1–9. Google Scholar
K. Tsuchiya, M. Ohuchi, N. Yamane, H. Aikawa, H. Gatanaga, S. Oka, A. Hamada,
High-performance liquid chromatography–tandem mass spectrometry for
simultaneous determination of raltegravir, dolutegravir and elvitegravir
concentrations in huma plasma and cerebrospinal fluid samples, Biomed.
Chromatogr. 32 (2018), e4058. Google Scholar
M Aouri, A Calmy, B Hirschel, A Telenti, T Buclin, M Cavassini, A Rauch, LA
Decosterd. A validated assay by liquid chromatography-tandem mass spectrometry
for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive
patients. J Mass Spectrom. 48(2013)616-625. Google Scholar
M. Cabrol, F. Dubois-Galopin, E. Chatelut, P. Delobel, P. Gandia, Determination of
dolutegravir’s unbound fraction in human plasma using validated equilibrium
dialysis and LC-MS/MS methods, Clin. Chim. Acta 479 (2018) 56–65. Google
Scholar
M Shibata, M Takahashi, M Yoshino, T Kuwahara, T Nomura, Y Yokomaku, W
Sugiura. Development and application of a simple LC-MS method for the
determination of plasma rilpivirine (TMC-278) concentrations. J Med Invest.
60(2013)35-40. Google Scholar
L Burugula, NR Pilli, A Makula, DS Lodagala, R Kandhagatla. Liquid
chromatographytandem mass spectrometric assay for the non-nucleoside reverse
transcriptase inhibitor rilpivirine in human plasma. Biomed Chromatogr.
27(2013)172-178. Google Scholar
Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in
antiretroviral-naive adults with HIV-1 infection: 48 week results from the
randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;
381(9868):735–43. [PubMed: 23306000]. Google Scholar